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ABSTRACT:  
Background: Early tumor shrinkage has been associated with improved survival in 
patients receiving cetuximab-based systemic chemotherapy for liver metastases from 
colorectal cancer (LM-CRC). We tested this hypothesis for previously-treated LM-
CRC patients receiving cetuximab (500 mg/m2) and triplet  hepatic artery infusion 
(HAI) within European trial OPTILIV.  
Methods: Irinotecan (180 mg/m2), 5–Fluorouracil (2800 mg/m2), and Oxaliplatin (85 
mg/m2) were given as chronomodulated or conventional delivery.  Patients were 
retrospectively categorized as early-responders (complete or partial RECIST 
response after 3 courses) or non-early-responders (late or no response). Prognostic 
factors were determined using multivariate logistic or Cox regression models.  
Results: Response was assessed in 57/64 registered patients (89%), who had 
previously received one to three prior systemic chemotherapy protocols. An early 
response occurred at 6 weeks in 16 patients (28%; 9 men, 7 women), aged 33-76 
years, with a median of 12 LM (2-50), involving 5 segments (1-8). Ten patients had a 
late response, and 31 patients had no-response. Grade 3-4 fatigue selectively 
occurred in the non-early-responders (0% vs 26%; p= 0.024). Early tumor response 
was jointly predicted by chronomodulation - odds ratio, OR: 6.0 [1.2 – 29.8] (p = 
0.029) - and LM diameter ≤ 57 mm - OR: 5.3 [1.1 – 25.0] (p = 0.033). Early tumor 
response predicted for both R0-R1 liver resection - OR: 11.8 [1.4 – 100.2] (p = 0.024) 
and overall survival - hazard ratio: 0.39 [0.17 – 0.88] (p = 0.023) in multivariate 
analyses.  
Conclusions: Early tumor response on triplet HAI and systemic cetuximab predicted 
for complete macroscopic liver resection and prolonged survival for LM-CRC patients 
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within a multicenter conversion-to-resection medico-surgical strategy. Confirmation is 
warranted for decision-making. 
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INTRODUCTION 
The addition of targeted therapy to standard chemotherapy regimens in the recent 
years has greatly improved the prognosis of metastatic colorectal cancer (mCRC), 
especially in patients with wild-type RAS[1, 2]. Cetuximab-based chemotherapy has 
achieved higher overall response rates, longer progression-free survival (PFS) and 
overall survival (OS) as compared with chemotherapy-only regimens for patients with 
mCRC in first-[3, 4], second-[5] and third-line treatments[6, 7]. The combination of 
cetuximab with oxaliplatin and/or irinotecan-based chemotherapy has further enabled 
curative intent liver resections with apparent survival improvements[8]. 
Achieving tumour shrinkage is an important goal of chemotherapy of LM-CRC, as it 
can translate into previously unforeseen surgical resections[9, 10]. Early tumor 
shrinkage could thus represent an important clinical objective for rapid symptoms 
relief  , identification of best candidates for LM conversion-to-resection[11, 12] and 
ultimately overall survival (OS) improvement.  
Retrospective analyses of randomized clinical trials have suggested a robust 
association between early tumor shrinkage by 20% or more and OS, independently 
of treatment arm[13, 14]. In contrast large increases in objective “best” response 
rates modestly translated into OS benefits for first line chemotherapy in patients with  
mCRC[15, 16]. Early tumor shrinkage could thus help guide and optimize medico-
surgical treatment strategies with curative intent. 
The present retrospective analysis evaluates for the first time the relevance of tumor 
response earliness on hepatic artery infusion (HAI) of combination chemotherapy for 
efficacy outcomes. The combination of triplet HAI and intravenous cetuximab 
achieved an exceptionally high efficacy in previously-treated patients with KRAS wt 
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metastatic colorectal cancer within European Phase II trial OPTILIV[17]. Objective 
response rate was similar to that reported for 1st line systemic chemotherapy, while 
30% of the registered patients underwent successful conversion-to-resection of 
extensive liver metastases[17].  
 
PATIENTS AND METHODS 
OPTILIV methodology was recently reported[17] and it is summarized below. 
Patients  
After approval by the regulatory authorities in France, Belgium, Portugal and Italy, the 
patients were enrolled in nine centers from 5/2008 to 3/2012. The patients had 
histological or cytological proof of colorectal adenocarcinoma, with wild type exon 2 
KRAS. Liver metastases (LM) resection with curative intent had to be deferred at 
medico-surgical multidisciplinary review meetings. All inclusion and non-inclusion 
requirements have been reported[17]. Trial inclusion required at least one of the 
following criteria: (a) less than 30% residual liver expected after resection, (b) 
malignant disease in contact with either 3 hepatic veins, both portal veins, or the 
retrohepatic vena cava, (c) documented progressive disease on imaging or doubling 
of serum levels of carcino-embryonic antigen (CEA) or CA19.9 over the prior 90 days 
or less. Up to three extra-hepatic resectable lesions of ≤ 10 mm, prior exposure to 
oxaliplatin, irinotecan, 5-FU and/or cetuximab, or prior surgery for LM were allowed. 
 
Chemotherapy administration 
All the patients had an implanted HAI catheter placed surgically or radiologically one 
week or more before chemotherapy onset. A chemotherapy treatment course 
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involved the intravenous administration of cetuximab (500 mg/m2 over 2.30 h in the 
morning) followed with triplet HAI, combined with usual intravenous supportive 
medications. This association was repeated every two weeks. The triplet HAI 
involved irinotecan (180 mg/m2), oxaliplatin (85 mg/m²) and 5-fluorouracil (2800 
mg/m²) administered into the hepatic artery catheter as a conventional or a 
chronomodulated delivery scheme according to institution experience. Courses were 
given every two weeks. For chronomodulated delivery, Irinotecan was administered 
on day 2 as a 6-h sinusoidal infusion from 2:00 to 8:00, with peak flow rate at 5:00, 
Oxaliplatin was given as sinusoidal daily infusions from 10:15 to 21:45, with peak 
delivery rate at 16:00 on days 2, 3 and 4, and 5-Fluorouracil was administered as 
sinusoidal daily infusions from 22:15 to 9:45, with peak delivery at 4:00, in alternation 
with oxaliplatin, on days 2, 3 and 4). This treatment scheme was automatically 
delivered using a programmable in time multichannel pump (Melodie®, Axon Cable, 
Montmirail, France) connected to the HAI port using a 20G Huber needle. 
Conventional treatment administration consisted of a 1-h constant rate infusion of 
Irinotecan, then a 2-h constant rate infusion of Oxaliplatin on day 1, followed with a 
48-h flat infusion of 5-Fuorouracil. Treatment was delivered using the Alaris® Syringe 
Pump (San Diego, California, USA). To evaluate hepatic arterial supply and catheter 
function, all the patients underwent a contrast angiography before each treatment 
course. The same combination of cetuximab and triplet chemotherapy had to be 
administered intravenously in case of HAI discontinuation and also after liver 
metastases resection. 
 
 
Assessments 
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All the patients had a thoraco-abdomino-pelvic computed tomography (CT) scan 
before inclusion and after every 3 courses until protocol withdrawal. Anti-tumor 
activity was assessed at each center according to RECIST 1.0 criteria[18] and 
consisted in the relative change in the sum of the largest diameters of the target liver 
lesions between baseline evaluation and the subsequent ones in the absence of new 
lesions. Maximum response was classified as complete (CR), partial (PR), stable 
disease (SD) or progressive disease (PD). Early tumor response was defined as the 
achievement of CR or PR after the first 3 courses, while late- responses were 
documented after 4 courses or more. The non-early-response group included 
patients with late response, stable disease, or progression as best response.  The 
feasibility of liver resection was decided at systematic multidisciplinary evaluations 
after every 3 courses at each center. 
Hepatectomies were undertaken whenever a complete macroscopic resection with 
curative intent was deemed possible. An estimated residual liver of less than 30% 
after curative intent surgery, and/or tight disease contact with liver main vessels that 
contra-indicated initial curative intent liver metastases resection were considered 
criteria for not undertaking surgery. Clinical and biological assessments were 
performed before each course and involved blood cell counts, renal and liver serum 
biochemistry and plasma carcinoembryonic antigen (CEA) and CA19.9. Performance 
status and adverse events were graded according to WHO and NCI-CTCAE v3.0 
scales, respectively.  
 
Statistical design and analyses 
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OPTILIV aimed to increase the rate of macroscopic complete resection (R0 +R1) 
from a historical control rate of 15% (P0=0.15) on currently available systemic 
neoadjuvant chemotherapy up to 30% (P1=0.30), with α=5% and β=20%, according 
to the exact single-stage Phase II design method. This required the inclusion of 48 
assessable patients for the primary outcome. A 30% rate of non-evaluable patients 
was expected for technical reasons such as arterial complications, which could lead 
to HAI withdrawal within the first two months. As a result, the inclusion of 64 patients 
was planned. Patient characteristics, toxicities, response and conversion-to-resection 
rates were compared according to response earliness using Fisher exact test or 
Pearson Ki2-test. Progression free survival (PFS) and overall survival (OS) were 
computed using Kaplan-Meier method, and compared with Log Rank. PFS was 
defined as the time between inclusion and progression or relapse, OS from inclusion 
to last known to be alive or death; the cut-off date for follow-up was March 1st, 2016. 
Differences between groups were validated using Log-rank test.  
Univariate analyses identified those among the 12 following factors (with their 
reference definition) possibly impacting on early response: delivery schedule 
(chronotherapy), number of metastases per patient (≤10), liver spread (≤ 25%), prior 
LM surgery or radiofrequency (no), LM unilaterality (unilateral), largest LM diameter 
(≤ 57 mm, median), liver segments involved (≤ 6), age (≤ 58 years,  median), sex 
(male), number of prior chemotherapy lines (one), WHO PS (0), and cetuximab dose 
intensity over 3 courses (> 205 mg/m2/week).   
Joint predictive factors of early response and conversion-to-resection were 
determined using binary logistic regression method. The impact of early response 
and other factors on survival was assessed by computing hazard ratio calculated with 
Cox proportional hazard ratio model.  All analyses were performed with SPSS® 
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v18.0 software (Chicago, IL, USA). A p-value < 0.05 was considered statistically 
significant. 
 
RESULTS 
Patient characteristics 
Fifty-seven of 64 patients (89%) registered in OPTILIV from 5/2008 to 3/2012 were 
assessed for response and eligible for early tumor response analysis (Figure A). 
Seven patients were not considered because of HAI catheter-related technical issues 
including implantation failure (3 patients) or early complete dysfunction (4 patients).  
The study population included 37 males (64.9%) and 20 females (35.1%) aged from 
33 to 75 years (Table A).  All patients were previously treated with one to three 
systemic chemotherapy protocols. The majority of patients had extensive liver 
involvement with bilobar liver metastases (84.2%), a median of 10 LM (1 to 69) and 6 
segments involved (1 to 8). The largest metastasis diameters ranged from 15 to 172 
mm with a median of 57 mm. Patients received a total of 359 protocol courses, 
resulting in a median number of 6 courses per patient (2 to 20). Triplet chemotherapy 
was delivered as conventional delivery for 281 courses in 41 patients or as a 
chronomodulated infusion for 78 courses in 16 patients. The main cause of protocol 
discontinuation was catheter related-complications (62.5% of patients)[17].  
An objective response was documented in 26 patients (45.6%), being an early 
response for 16 patients (28%). The 41 patients (72%) with non-early-response 
included 10 late-responders (18%) and 31 non-responders (54%). Median time from 
protocol treatment onset to the first response evaluation was 6.4 weeks (range, 4.3 - 
10.6) for early responders and 6.1 weeks (range 3.9 - 15.9) for non-early responders 
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(P=0.45). The characteristics of early-response and non-early-response groups only 
differed for the diameter of the largest LM (median, 37 mm vs 60 mm; p from 
univariate analysis = 0.022) (Table A). Late-responders differed from non-responders 
with regard to bilobar liver lesions (12.5% vs 60.4% of patients respectively, 
p=0.024). The initial characteristics of the early responders were otherwise similar to 
those of the late responders. Median duration of HAI, from the first to the last protocol 
treatment day was 12.8 weeks (range, 5.9 - 51.6) for early responders, and 11.3 
weeks (range, 2.3 - 58.9) for non-early responders (p= 0.20). The median number of 
HAI courses given was 6 for both early (range, 3 to 11) and non-early responders, 6 
(2 - 20) (p= 0.54). 
Overall, the median relative dose intensities of chemotherapy were 82.3% for both 
cetuximab and irinotecan, 80% for oxaliplatin and 79% for 5-fluorouracil over 3 
courses. There was no significant difference between early responders and non-early 
responders.  The main grade 3-4 toxicities encountered were neutropenia, abdominal 
pain, leukopenia, fatigue and diarrhea (Table B). Grade 3-4 fatigue was documented 
in none of the early responders, as compared to 11/41 patients (26.8%) in the non-
early-response group (p=0.024). 
 
Predictive factors of early tumor response 
The diameter of the largest LM was significantly associated with an early tumor 
response. Thus,  an early response was achieved in 11.5% (3/26) of the patients with 
a largest LM diameter > 57 mm as compared to  41.9% (13/31) of those whose 
largest LM was  57 mm (univariate analysis, p=0.011). Both a largest LM diameter ≤ 
57 mm (p = 0.033) and chronomodulated HAI delivery (p=0.029) were joint predictive 
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factors of an early response, with respective Hazard ratio (HR) of 5.3 [95% CL; 1.1 – 
25.0] and 6.0 [95% CL; 1.2 – 29.8]. 
Impact of early-response on complete macroscopic liver resection rate 
Seventeen patients (29.8%) underwent macroscopically complete LM resection, 
including single-stage hepatectomy (14 patients), two-stage (2 patients) or three-
stage (one patient). Partial hepatectomy was associated with radiofrequency ablation 
for five patients and portal embolization for one patient. Liver surgery was performed 
after a median treatment duration of 5.3 months (range, 2.6 to 19.3), without any 
statistically significant difference according to early vs non-early response. 
Seven of 16 early responders (43.8%) underwent R0-R1 liver surgery, including 5/5 
on chronotherapy (100%) and 2/12 (16.7%) on conventional delivery. The other 
factors significantly associated with increased R0-R1 resection rates were a number 
of LM ≤ 10, and a single prior chemotherapy line. Joint positive predictors of R0-R1 
resection included early tumor response (HR = 11.78, p= 0.024), > 10 LM (HR = 
0.004, p = 0.001), a single prior chemotherapy protocol (HR = 20.8, p = 0.007) and 
an age < 58 years (HR = 10.95, p = 0.026), according to multivariate logistic 
regression analysis. 
 
Relevance of early-response for progression-free survival (PFS) and overall 
survival (OS) 
Median PFS was 2 months longer in early-responders as compared to the non-early 
responders - 11.6 months [95% CL, 5.4 -17.8] vs 9.3 [6.0 - 12.6] (Table C). However, 
early response was not identified as a statistically significant prognostic indicator of 
PFS according to both univariate and multivariate analyses.  
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Median OS was 14.9 months longer in the early-responders as compared to the non-
early responders – 35.1 months [33.8 – 36.4]  vs 20.2 [13.7 – 26.8] (p from Log Rank 
= 0.01, Figure B). Multivariate analysis confirmed early response as an independent 
predictive factor of OS (HR = 0.39; p=0.023), jointly with the following conditions: R0-
R1 resection (HR=0.25; p=0.001), liver involvement ≤ 25% (HR=0.40; p=0.03), a 
single prior chemotherapy protocol (HR = 0.43, p=0.014), and age > 58 years 
(HR=0.41, p=0.02). No statistically significant effect was found for sex, primary tumor 
site (colon vs rectum), liver only disease, largest metastasis diameter, WHO PS, or 
acneiform rash  (Figure C). Subgroup analysis further suggested the survival benefit 
resulting from an early response was strongly associated with chronomodulated 
delivery (Figure D).  
 
DISCUSSION 
OPTILIV is the first prospective multicenter trial worldwide involving the 
administration of the three major chemotherapy drugs against CRC (irinotecan, 
oxaliplatin and 5-fluorouracil) into the hepatic artery in order to convert-to-resection 
initially unresectable LM. Such liver-targeted chemotherapy modality aimed to 
achieving direct contact of drugs with the tumor cells into the liver, thereby enhancing 
tumor cell death and reducing the risk of hepatic relapse[19, 20].  This mechanism 
should thus both accelerate and increase magnitude of LM shrinkage[19]. A prior 
salvage study offered an initial proof of this therapeutic concept in 29 patients 
receiving chronomodulated HAI of irinotecan, 5-fluorouracil and oxaliplatin for 
unresectable liver metastases, following failure of a median of four prior systemic 
chemotherapy protocols[21]. OPTILIV further combined chronomodulated or 
conventional triplet HAI delivery with intravenous cetuximab in 64 patients with prior 
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exposure to one to three chemotherapy protocols for extensive LM from KRAS wt 
colorectal cancer[17].  
Early-tumor shrinkage was proposed as a surrogate endpoint for predicting long-term 
outcome of patients on cetuximab-based systemic chemotherapy[13, 14]. Yet the 
time to first tumor assessment, the method and the cut-off of relative changes in 
tumor size remain unsettled.  In recent years, clinical studies showed that the 
addition of targeted agents to chemotherapy could induce tumor necrosis without 
significant changes in tumor size[22, 23]. These findings made it difficult to define 
any clinically-relevant cut-off limit for tumor shrinkage. This was illustrated in our 
study as well, since nine patients underwent successful liver resection, despite no 
objective response being documented using conventional RECIST criteria. However, 
tumor size reduced by a median value of 18% (0 to -29%) in these patients. In the 
same way, no significant association was found here between overall best objective 
response and complete macroscopic liver resection. Recent retrospective studies[12, 
13, 24, 25] have addressed this issue through considering early tumor shrinkage as a 
better indicator of more stringent efficacy outcomes. They defined early tumor 
response as a relative change of ≥ 20% in the sum of the largest diameters of target 
lesions at nearly 8 weeks compared to baseline. In this setting, Ye L.C. et al[11] and 
Douillard J.Y.[12] demonstrated that macroscopic liver resection was significantly 
associated with early tumor response on intravenous chemotherapy. In the present 
analysis, we determined both early and late responses according to RECIST criteria, 
qualifying early response as a PR or CR after three treatment courses. Early tumor 
response significantly predicted for conversion-to-resection on triplet HAI and iv 
cetuximab.  Our study further emphasized the possible role of chronomodulated 
triplet HAI for maximizing the chances of an early response.  Thus, chronotherapy 
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induced twice as many early responses as compared to conventional delivery (44% 
vs 22%), resulting in more R0-R1 resections (31% vs 5%), and a better overall 
survival. These data obtained in a limited yet multicenter patient sample support 
further prospective randomized evaluation. 
Statistically significant longer PFS and OS have been reported in patients with early 
tumor shrinkage ≥ 20% as compared to those without early shrinkage in several 
studies[24-28]. Early response was here associated with a non-statistically significant 
PFS prolongation by 2 months as compared to non-early response. The median OS 
of early responders however was prolonged by 14.9 months, as compared to non-
early responders, and by 23 months as compared to late responders. Such finding 
further suggests that the achievement of an early response could represent a critical 
therapeutic endpoint for future studies aiming at enhancing conversion-to-resection 
of metastatic disease and/or overall survival. In the current study, no grade 3-4 
fatigue was observed among the early responders as compared to 27% in the non-
early responders. This finding is consistent with reported improved tolerability and 
quality of life associated with an early response on intravenous chemotherapy[29].  
However, we wish to emphasize the small sample size of our study and the high 
incidence of catheter-related issues, which however did not impair treatment efficacy 
or patient condition. From a clinical perspective, we feel that patients with initially 
unresectable liver metastases from CRC should be offered OPTILIV protocol at an 
early stage of the course of their metastatic liver disease. This would expectedly 
maximize their chances of an early tumor response, secondary R0-R1, and 
prolonged survival, while minimizing adverse events through short treatment 
duration. 
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In conclusion, the present study showed that an early tumor response predicted for 
increased LM conversion-to-surgery rate and prolonged survival in previously-treated 
patients receiving triplet hepatic artery infusion and systemic cetuximab for initially 
unresectable liver metastases from colorectal cancer. The concept of “early tumor 
response” on HAI therapies deserves further prospective trials, as it may help guide 
and optimize curative intent medico-surgical strategies in patients with liver 
metastases from colorectal or other malignancies. 
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